US OptionsDetailed Quotes
BCTX250117C7500
- 0.05
- 0.000.00%
15min DelayClose Dec 24 13:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume189 Open Interest7.50Strike Price0.00Turnover633.70%IV1308.58%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1909Delta0.3205Gamma10.74Leverage Ratio-0.0050Theta0.0000Rho2.05Eff Leverage0.0004Vega
BriaCell Therapeutics Stock Discussion
Sign in to post a comment
$BriaCell Therapeutics (BCTX.US)$ hi guys, im quite new to stocks, just want to check is there potential growth in this stocks for long? Thanks
1
$Gorilla Technology (GRRR.US)$ PR: CEO will have interview with Red Chip Small Stock, Big Money show on Sat Dec 14. Reports on CEO on X that they have been selected from the shortlist for the $438M deal in SE Asia. Low float. $23.2M cash good for 12 months
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
30
31
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$BriaCell Therapeutics (BCTX.US)$ Briacell Therapeutics Highlights The Infiltration Of Cancer Fighting Immune Cells Into Tumors, Using CD8 ImmunoPET Imaging Technology, In Its Poster Presentation At 2024 San Antonio Breast Cancer Symposium
Benzinga· 1 min ago
Benzinga· 1 min ago
1
2
$BriaCell Therapeutics (BCTX.US)$
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
Friday, 13th December at 7:50 am
BriaCell reports influx of cancer fighting CD8+ "killer" T cell into metastatic breast cancer tumors and lymph organs turning "Cold" tumors and lymph nodes "Hot" on ImmunoPET imaging in cancer patients treated with Bria-IMT™ plus an immune checkpoint inhibitor (CPI)
Imaging confirms clinical...
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
Friday, 13th December at 7:50 am
BriaCell reports influx of cancer fighting CD8+ "killer" T cell into metastatic breast cancer tumors and lymph organs turning "Cold" tumors and lymph nodes "Hot" on ImmunoPET imaging in cancer patients treated with Bria-IMT™ plus an immune checkpoint inhibitor (CPI)
Imaging confirms clinical...
3
$BriaCell Therapeutics (BCTX.US)$ Bearish news - Offering but no bad news about the company. Low risk, big reward potential imo. My SL below 0.50.
1
5
$BriaCell Therapeutics (BCTX.US)$ Reuters· 2 mins ago
Briacell Therapeutics Announces Proposed Public Offering
Briacell Therapeutics Announces Proposed Public Offering
3
19
$BriaCell Therapeutics (BCTX.US)$
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Wednesday, 11th December at 7:50 am
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting...
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Wednesday, 11th December at 7:50 am
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting...
$BriaCell Therapeutics (BCTX.US)$ Pending good news leak out ?
1
No comment yet
hopeful Andy : yes but not at the moment